The record provides evidence for diagnostic discrimination rather than treatment efficacy; if externally validated, earlier recognition of intracranial germ cell tumors could plausibly reduce misdiagnosis and treatment delay, but improved therapeutic outcomes remain an inference.

The evidence supports FDG-PET/CT as a potentially effective rule-out staging test in this cohort; it may therefore permit omission of invasive marrow procedures and reduce procedural burden, but this clinical benefit remains an inference requiring prospective validation, particularly in rhabdomyosarcoma.

The evidence shows an association between prior cancer and higher mortality during longer-term pediatric VAD support; it can be hypothesized, but is not demonstrated, that oncology-specific risk stratification and tailored supportive care could improve selection or management of children with cancer histories who require VADs.

The observational evidence supports severe neutropenia and steroid exposure as potential risk markers for early port infection; it suggests—but does not establish—that antibiotic prophylaxis or delaying placement during severe neutropenia could reduce infection risk and should be tested prospectively.

The study provides evidence of reported physiotherapy referrals, utilisation, and access barriers; it supports the hypothesis—but does not demonstrate—that improved referral pathways and reduced financial barriers could increase rehabilitation uptake and potentially improve function or quality of life in children with cancer.

The study provides evidence that a structured set of clinical indicators may help nurses identify inadequate nutritional intake in children with cancer; it is an inference, not tested here, that earlier recognition followed by targeted nutritional support could reduce complications or improve cancer-treatment outcomes.

The survey provides evidence of unmet survivorship-care needs and preferences; it supports—but does not test—the hypothesis that structured, risk-adapted follow-up with proactive education, psychological support, dedicated contacts, and sustainable financing could improve late-effect detection, care satisfaction, and survivor outcomes.

The study provides associative evidence that social interaction and social media are perceived as protective connection strategies, but it does not test an intervention; it is reasonable to hypothesize that loneliness screening and structured, developmentally appropriate social-connection support could improve psychosocial outcomes during cancer therapy, pending prospective evaluation.

The evidence identifies potentially actionable supportive-care gaps but does not test an intervention; it is reasonable to hypothesize that context-sensitive multidisciplinary support, improved communication, social support, spiritual-care integration, and insurance access could reduce unmet needs, although prospective intervention studies are required.

The evidence shows that MRI can identify rare lesions with implications for growth hormone treatment eligibility and referral; by inference, a validated risk-adapted imaging strategy might preserve detection of these lesions while reducing unnecessary imaging, but this study does not establish such a strategy prospectively or demonstrate improved outcomes.

The reviewed evidence suggests that adult HPV vaccination may reduce some HPV infections and related disease outcomes; it is an inference—not established by this narrative review—that broader life-course vaccination could prevent later HPV-associated cancers or post-treatment recurrence, with only indirect relevance to pediatric oncology.

The reported cases support early recognition, thorough staging, and multimodal local and radioactive iodine treatment as clinically relevant management considerations; it is only an inference—not tested here—that molecular stratification or alternative RET-focused testing could eventually guide targeted therapy or treatment selection.